NCPA: Pharmacists Prescribing Paxlovid a Welcome Course Correction by FDA

FDA move will increase patient access to vital therapies, community pharmacy says

NCPA July 6, 2022

ALEXANDRIA, Va. (July 6, 2022) – After months of advocacy by the National Community Pharmacists Association and other organizations, the Food and Drug Administration has revised the Emergency Use Authorization for Paxlovid to authorize state-licensed pharmacists to prescribe it to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing.

NCPA issued the following statement from CEO B. Douglas Hoey, pharmacist, MBA, reacting to this development:

“Pharmacists are the drug therapy and drug interaction experts. This move opening up their ability to assess the need for and prescribe Paxlovid will improve patients’ timely access to treatments that will help keep them out of the hospital and alive.

“We’re grateful to the FDA for engaging with us on this issue and appreciate the agency’s course correction. But to further support a successful COVID-19 oral antiviral program, the Biden administration and payers also must ensure appropriate payment for the pharmacist assessing the patients, performing drug and disease interaction checks, and working with physician colleagues on proper prescribing.”


Founded in 1898, the National Community Pharmacists Association is the voice for the community pharmacist, representing nearly 19,400 pharmacies that employ approximately 215,000 individuals nationwide. Community pharmacies are rooted in the communities where they are located and are among America’s most accessible health care providers. To learn more, visit